Printer Friendly

IMMUNOMEDICS REPORTS ON LYMPHOMA IMAGING AND THERAPY PROGRESS AT CANCER CONFERENCE

 MORRIS PLAINS, N.J., May 19 /PRNewswire/ -- Immunomedics, Inc. (NASDAQ: IMMU), reported advances in lymphoma imaging and therapy at The American Association for Cancer Research Conference in Orlando, Fla. In a study presented by Dr. George Q. Mills, vice chief, nuclear medicine at Our Lady of the Lake Regional Medical Center, Baton Rouge, La., the application of ImmuRAID(TM)-LL2, Immunomedics' imaging agent for the detection of non-Hodgkin's B-cell lymphoma, resulted in an imaging sensitivity of nearly 100 percent, correctly identifying at least one known lesion in each of the 10 patients. In separate presentations, Immunomedics' scientists reported on the company's efforts to treat lymphoma, including promising results with its humanized version of the LL2 antibody and pre-clinical data with a rhenium-labeled antibody.
 Immunomedics' lymphoma imaging and therapy agents are under study at medical centers in the United States and Europe. The company is currently conducting a Phase I/II trial of its lymphoma therapeutic agent, ImmuRAIT(TM)-LL2, consisting of a radiolabeled (I-131) antibody, and is completing Phase II studies with ImmuRAID-LL2, its lymphoma imaging agent that uses the radioisotope technetium-99m attached to an antibody fragment.
 According to Dr. Mills, "ImmuRAID-LL2 was highly sensitive for the detection of lymphoma and was able to identify undiagnosed lesions. No adverse reactions were observed in the patients and the diagnostic imaging quality of the study was determined to be of a high level."
 Dr. Shawn Leung, Immunomedics' director, molecular biology, reported that activity of its humanized form of the LL2 lymphoma antibody maintains full immunoreactivity and that it internalizes as rapidly as its murine antibody counterpart. According to Dr. Leung, "this confirms our belief that the humanized molecule retains the desirable antigen targeting and binding features of a mouse antibody. This humanized version will be best suited for repeated therapeutic applications in lymphoma patients."
 Dr. Gary L. Griffiths, Immunomedics' director, chemistry and radioimmunology, presented a study revealing that tumor-bearing severe combined immunodeficient (SCID) mice given a monoclonal antibody labeled with the radioisotope Rhenium-188 showed an increased mean life expectancy of almost 50 percent. These results were achieved with Immunomedics' proprietary one-step direct labeling method for preparing the Rhenium-188 LL2 (lymphoma) antibody. Immunomedics is currently studying the effect of different dose regimens on life-extension. Dr. Griffiths commented that "by using rhenium, we hope to develop an effective outpatient therapy for non-Hodgkin's B-cell lymphoma, which afflicts 36,000 Americans annually."
 Mr. David W. Ortlieb, Immunomedics' president & CEO commented that, "we believe we are the only company with monoclonal antibody-based products for lymphoma imaging and therapy in clinical trials, and these results highlight our position. Our strategy is to take the same technology used in our imaging agents, improve upon it through antibody humanization, thereby creating viable therapeutic agents."
 Immunomedics is a biopharmaceutical company applying innovative technology in antibody selection, modification and chemistry to the development of products for the detection and treatment of cancers and infectious diseases. Integral to these products are highly specific monoclonal antibodies designed to deliver radioisotopes, chemotherapeutic agents or toxins to tumors and sites of infections or other diseases. The company currently has one therapeutic and five imaging products in human clinical trials. In addition, the company's colorectal cancer imaging agent, ImmuRAID(TM)-CEA, is under review for marketing approval by the U.S. Food and Drug Administration, as well as by regulatory agencies in Europe and Canada.
 -0- 5/19/93
 /CONTACT: Debra Wasser, director of corporate communications, Immunomedics Inc., 201-605-1330 ext. 113/
 (IMMU)


CO: Immunomedics, Inc. ST: New Jersey IN: MTC SU:

LD -- NY003 -- 0105 05/19/93 08:00 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 19, 1993
Words:593
Previous Article:DIGITAL BIOMETRICS ANNOUNCES TENPRINTER SYSTEM ORDERS
Next Article:HERTZ AND AIR FRANCE SIGN GLOBAL PARTNERSHIP AGREEMENT
Topics:


Related Articles
IMMUNOMEDICS PURSUES NEW CANCER THERAPY; PATENT ALLOWED FOR METHOD COMBINING CYTOKINES AND RADIOACTIVE ANTIBODIES
IMMUNOMEDICS ALLOWED PATENT FOR NEW CANCER IMAGING & THERAPY METHODS & AGENTS: FEDERAL GRANT FOR CANCER THERAPEUTIC ALSO AWARDED
IMMUNOMEDICS RECEIVES BROAD EUROPEAN PATENT FOR HIGHLY SPECIFIC CANCER TARGETING ANTIBODIES
IMMUNOMEDICS REPORTS INITIAL CLINICAL RESULTS OF A NEW CANCER THERAPEUTIC; ANTIBODY HUMANIZATION PROGRAM ALSO ADVANCES
IMMUNOMEDICS REPORTS PROMISING LYMPHOMA THERAPY RESULTS; CLINICAL FINDINGS PRESENTED AT ANNUAL NUCLEAR MEDICINE MEETING
IMMUNOMEDICS GRANTED THREE PATENTS IN JAPAN
IMMUNOMEDICS MAKES ADVANCES IN ANTIBODY RECONSTRUCTION AND HUMANIZATION; PROGRESS IN CANCER THERAPY PROGRAMS REPORTED
Patent awarded to Immunomedics for lymphoma treatment licensed to Amgen.
Immunomedics obtains patent for therapy of B-cell malignancies using antibodies.
Immunomedics obtains lymphoma antibody patent.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters